{"id":72782,"date":"2019-11-07T17:47:00","date_gmt":"2019-11-07T15:43:00","guid":{"rendered":"https:\/\/hispanicprwire.com\/english-results-from-prospective-multicenter-trial-evaluating-the-use-of-the-tablo-hemodialysis-system-for-home-dialysis-released-at-the-american-society-of-nephrology-scientific-meeting\/"},"modified":"2019-11-07T18:48:02","modified_gmt":"2019-11-07T22:48:02","slug":"los-resultados-de-estudio-prospectivo-y-multicentrico-que-evalua-el-empleo-del-sistema-de-hemodialisis-tablo-para-la-dialisis-domiciliaria-se-divulgan-en-encuentro-cientifico-de-la-sociedad-esta","status":"publish","type":"post","link":"https:\/\/hispanicprwire.com\/en\/los-resultados-de-estudio-prospectivo-y-multicentrico-que-evalua-el-empleo-del-sistema-de-hemodialisis-tablo-para-la-dialisis-domiciliaria-se-divulgan-en-encuentro-cientifico-de-la-sociedad-esta\/","title":{"rendered":"Results from Prospective, Multicenter Trial Evaluating the Use of the Tablo\u00ae Hemodialysis System for Home Dialysis Released at the American Society of Nephrology Scientific Meeting"},"content":{"rendered":"<p><\/p>\n<style type=\"text\/css\"><![CDATA[\n\/* Style Definitions *\/\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n]]><\/style>\n<div class=\"xn-content\">\n<p><b><i>First New Device Trial Completed for Home Hemodialysis In 15 Years<\/i><\/b><\/p>\n<p><span class=\"xn-location\">SAN JOSE, California<\/span>, <span class=\"xn-chron\">Nov. 7, 2019<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing, global, dialysis market today announced publication of a multicenter, prospective, open-label study in <b>Hemodialysis International<\/b>.\u00a0 Titled &#8220;Safety and Efficacy of the Tablo Hemodialysis System for In-center and In-home hemodialysis,&#8221; the 30-patient study met both the safety and efficacy endpoints.\u00a0 Tablo is currently FDA-cleared for use in hospitals and clinics and is under evaluation by FDA for use in the home.<\/p>\n<div id=\"prni_dvprnejpgac98left\" style=\"WIDTH: 100%; TEXT-ALIGN: left\" dir=\"ltr\"><img decoding=\"async\" id=\"prnejpgac98left\" title=\"The Tablo Hemodialysis System\" border=\"0\" alt=\"The Tablo Hemodialysis System\" align=\"middle\" imagelabel=\"General\" src=\"https:\/\/mma.prnewswire.com\/media\/1004571\/Outset_Medical_Tablo.jpg\"\/><\/div>\n<p>Over 21 consecutive weeks, patients went through four treatment periods in which hemodialysis was prescribed four times weekly: \u00a0one-week Run-In; eight-week In-Center; four-week Transition; eight-week In-Home. \u00a0The data showed a mean weekly standard Kt\/V \u2265 2.8 for participants during the In-Center and In-Home treatment periods (compared to the trial endpoint of a standard Kt\/V \u2265 2.1) and delivered ultrafiltration (UF) within 10% of prescribed UF. \u00a0There were no device-related pre-specified adverse events throughout the trial.\u00a0 All patients who started the home arm with Tablo completed it, resulting in a 0% home arm drop-out rate. \u00a0<\/p>\n<p>&#8220;The trial results and patient feedback were compelling,&#8221; said <span class=\"xn-person\">Troy Plumb<\/span>, M.D., principal investigator of the study and Division Chief of Nephrology and Associate Professor of Medicine at the <span class=\"xn-org\">University of Nebraska Medical Center<\/span> College of Medicine in Omaha.\u00a0 &#8220;Many patients have expressed enthusiasm for home use since they want more lifestyle flexibility and control of their care.&#8221; <\/p>\n<p>In addition to online publication of the study on <span class=\"xn-chron\">November 7<\/span>, Dr. Plumb will be presenting the data in <span class=\"xn-location\">Washington, D.C.<\/span> this week at the American Society of Nephrology annual scientific meeting.\u00a0 <\/p>\n<p>&#8220;The results of this study suggest the success patients can have when they manage their dialysis care at home,&#8221; said Outset Medical Chief Executive Office Leslie Trigg.\u00a0 &#8220;We believe a new technology option for patients who want to dialyze at home will help support the White House initiative to improve care and expand treatment in the home.&#8221; <\/p>\n<p>Outset Medical&#8217;s Chief Medical Officer, nephrologist <span class=\"xn-person\">Michael Aragon<\/span>, M.D., added, &#8220;More than 500,000 Americans are on dialysis, and approximately 100,000 more begin treatment each year.\u00a0 The more that care can be easily accessible, the better it is for patients and our country&#8217;s health care system.&#8221; <\/p>\n<p><b>About the Tablo System<\/b><\/p>\n<p>Tablo was designed in Silicon Valley to reduce the cost and complexity of dialysis care. Requiring only an electrical outlet and tap water to operate, the small, mobile Tablo system frees patients and providers from expensive clinic infrastructure.\u00a0 The machine&#8217;s functionality enables it to serve as a dialysis clinic on wheels. Wireless data, sensor-based automation and an animated touchscreen make the system easy to learn and use.\u00a0 <\/p>\n<p><b>About Outset Medical<\/b><\/p>\n<p>Silicon Valley-based Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience. Outset&#8217;s Tablo System is CE-marked and FDA-cleared for use in acute and chronic care settings.\u00a0 In October, the U.S. Department of Health and Human Services (HHS) awarded Outset Medical a contract for the use of the Tablo in communities hit by natural disasters.\u00a0 This year, Outset also was named a winner of the Kidney X Redesign Dialysis Competition sponsored by the Department of HHS and the American Society of Nephrology. <\/p>\n<p>For more information, visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2636211-1&amp;h=2070520128&amp;u=http%3A%2F%2Fwww.outsetmedical.com%2F&amp;a=www.outsetmedical.com\" rel=\"nofollow\">www.outsetmedical.com<\/a> and follow the company on Twitter at @OutsetMedical.<\/p>\n<p>Photo &#8211; <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2636211-1&amp;h=982888868&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1004571%2FOutset_Medical_Tablo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1004571%2FOutset_Medical_Tablo.jpg\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/1004571\/Outset_Medical_Tablo.jpg<\/a> <\/p>\n<p>SOURCE  Outset Medical<\/p>\n<\/div>\n<p> <\/p>","protected":false},"excerpt":{"rendered":"<div class=\"xn-content\">\n<p><b><i>First New Device Trial Completed for Home Hemodialysis In 15 Years<\/i><\/b><\/p>\n<p><span class=\"xn-location\">SAN JOSE, California<\/span>, <span class=\"xn-chron\">Nov. 7, 2019<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing, global, dialysis market today announced publication of a multicenter, prospective, open-label study in <b>Hemodialysis International<\/b>.\u00a0 Titled &#8220;Safety and Efficacy of the Tablo Hemodialysis System for In-center and In-home hemodialysis,&#8221; the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72783,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[37],"tags":[],"class_list":["post-72782","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured"],"acf":[],"_links":{"self":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/72782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/comments?post=72782"}],"version-history":[{"count":0,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/72782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/media\/72783"}],"wp:attachment":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/media?parent=72782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/categories?post=72782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/tags?post=72782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}